Age-related macular degeneration (AMD) is the main cause of visual impairment in developed countries. Several improvements in the visualization of posterior segment of the eye together with the introduction of intravitreal anti-VEGF treatment have revolutionized the prognosis of the wet form of AMD (wAMD). Increasing incidence of wAMD together with the limited resources of the healthcare systems pose challenges for the provision and development of care. In context of these current aspects, we aim to set evidence-based medicine guidelines for diagnosis, treatment and follow-up of patients with wAMD.
Kai Kaarniranta (Chair)